Innate Pharma S.A.

IPHA | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.86

-$0.04 (-2.11%)

At close: Sep 21, 2026, 4:00 PM ET

$1.85

-$0.01 (-0.54%)

After-hours: Sep 21, 2026, 5:06 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.11%

(1D)

Rating

Updated: Sep 10, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $174.66M

1D Range

1.79 1.87

52W Range

1.17 2.71

Valuation (TTM)

PE -3.13

PB -3.78

EV/EBITDA -2.91

Valuation (NTM)

Forward PE 40.01

Forward PEG 0.14

Price Target $6.67

Cash Flow

FCF Yield -29.4%

SBC Adj. FCF Yield -29.4%

SBC Impact N/A

Margins

Gross Margin 1770.3%

Operating Margin -4598.8%

FCF Margin -4142.3%

Growth (CAGR)

Revenue 3Y | 5Y -72.8% | -51.7%

Dil EPS 3Y | 5Y -26.8% | 12.3%

FCF 3Y | 5Y -28.7% | 21.9%

Returns

ROA -136.7%

ROE 152.6%

ROIC -380.7%

Financial Health

Net Debt

€9.26M ($10.58M)

Current Ratio 0.60

Interest Coverage -17.47

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. T...

Sector Healthcare

Industry Biotechnology

Employees 163

IPO Date Oct 16, 2019

Website www.innate-pharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+276.34%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞